First-Line Treatment for Locally Advanced or Metastatic Mesenchymal Epithelial Transition Factor (MET) - Positive Gastric, Lower Esophageal, or Gastroesophageal Junction (GEJ) Adenocarcinoma

NCT01697072 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

609

Enrollment

INDUSTRY

Sponsor class

Stopped All Amgen sponsored AMG102 clinical studies were terminated following a pre-planned Data Monitoring Committee safety review of study 20070622.

Conditions

Gastric Cancer

Interventions

DRUG: Rilotumumab
OTHER: Placebo
DRUG: Epirubicin
DRUG: Cisplatin
DRUG: Capecitabine

Sponsor

Amgen